Search
Please choose your country
more info

Contact:
Phone:+49 0761 1514 440 Fax:+49 0761 1514 460 Email: info@falkfoundation.org

Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Edition 3/2026

Edition 2/2026

Edition 1/2026

This page provides access to all FGR publications selected from international medical journals since mid-2022. Click above to browse one of the three most recent issues. If you are looking for an older issue, organ-related topics or specific indications, simply use the filters below.

All articles

Liver and Bile

Urine is a viral antigen reservoir in hepatitis E virus infection

Hepatology. 2023;77(5):1722–34

Ying D, He Q, Tian W, Chen Y, Zhang X, Wang S, Liu C, Chen Z, Liu Y, Fu L, Yan L, Wang L, Tang Z, Wang L, Zheng Z, Xia N

Liver and Bile

Acute severe non-A-E-hepatitis of unknown origin in children – A 30-year retrospective observational study from North-West Germany

J Hepatol. 2023;78(5):971–8

Leiskau C, Tsaka S, Meyer-Ruhnke L, Mutschler FE, Pfister ED, Lainka E, Baumann U

Liver and Bile

PNPLA3 genotype and diabetes identify patients with non-alcoholic fatty liver disease at high risk of incident cirrhosis

Gastroenterology. 2023;164(6):966–77.e17

Chen VL, Oliveri A, Miller MJ, Wijarnpreecha K, Du X, Chen Y, Cushing KC, Lok AS, Speliotes EK

Liver and Bile

The global epidemiology of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A systematic review

Hepatology. 2023;77(4):1335–47

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L

Liver and Bile

Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: A randomized, placebo-controlled phase 2 trial

Lancet Gastroenterol Hepatol. 2023;8(6):511–22

Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, Lawitz E, Ratziu V, Sanyal AJ, Schattenberg JM, Newsome PN; NN9931-4492 investigators

Liver and Bile

Role of rifaximin in the management of alcohol-associated hepatitis: A systematic review and meta-analysis

J Gastroenterol Hepatol. 2023;38(5):703–9

Ahmed Z, Badal J, Nawras M, Battepati D, Farooq U, Arif SF, Lee-Smith W, Aziz M, Iqbal U, Nawaz A, Gangwani MK, Iqbal A, Kobeissy A, Addissie BD, Hassan M, Saab S

Liver and Bile

Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: A multicenter cohort study

J Gastroenterol Hepatol. 2023;38(4):648–55

Cho SH, Song TJ, Park JS, Yoon JH, Yang MJ, Yoon SB, Lee JM, Lee YN, Kim SH, Choi EK, Park SW, Oh D, Park DH, Lee SS, Seo DW, Lee SK, Kim MH

Liver and Bile

Long-term outcomes of patients with type 1 or 2 autoimmune hepatitis presenting in childhood

J Hepatol. 2023;78(5):979–88

Maggiore G, Bernard O, Mosca A, Ballot E, Johanet C, Jacquemin E

Liver and Bile

Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration

Hepatology. 2023;77(4):1095–105

Díaz-González Á, Hernández-Guerra M, Pérez-Medrano I, Sapena V, Riveiro-Barciela M, Barreira-Díaz A, Gómez E, Morillas RM, Del Barrio M, Escudé L, Mateos B, Horta D, Gómez J, Conde I, Ferre-Aracil C, El Hajra I, Arencibía A, Zamora J, Fernández A, Salcedo M, Molina E, Soria A, Estévez P, López C, Álvarez-Navascúes C, García-Retortillo M, Crespo J, Londoño MC; ColHai Registry